{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:17:34Z","timestamp":1783030654367,"version":"3.54.6"},"reference-count":178,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,11]],"date-time":"2027-02-11T00:00:00Z","timestamp":1802304000000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["K24AI143447"],"award-info":[{"award-number":["K24AI143447"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.molmed.2025.08.003","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T20:22:39Z","timestamp":1756498959000},"page":"143-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cholesterol efflux in HIV-associated atherosclerosis: mechanisms and targets"],"prefix":"10.1016","volume":"32","author":[{"given":"Emily","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh","family":"Chidambaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amudha","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah G.","family":"Cotto Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen","family":"Golzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Pyslar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawahar L.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros C.","family":"Karakousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2025.08.003_bb0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.molmed.2025.08.003_bb0010","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/S2352-3018(23)00272-2","article-title":"Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies","volume":"11","author":"Trickey","year":"2024","journal-title":"Lancet HIV"},{"key":"10.1016\/j.molmed.2025.08.003_bb0015","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2025.08.003_bb0020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012241","article-title":"HIV Infection and incidence of cardiovascular diseases: an analysis of a large healthcare database","volume":"8","author":"Alonso","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.molmed.2025.08.003_bb0025","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/jac\/dkae049","article-title":"Changes in atherosclerotic cardiovascular disease risk over time among people living with HIV","volume":"79","author":"Chen","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.molmed.2025.08.003_bb0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/CIRCULATIONAHA.122.057443","article-title":"Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context","volume":"147","author":"Ntsekhe","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2025.08.003_bb0035","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jacc.2023.04.050","article-title":"Dyslipidemia in human immunodeficiency virus disease","volume":"82","author":"Kalra","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107812","article-title":"HIV infection, antiretroviral therapy and vascular dysfunction: effects, mechanisms and treatments","volume":"217","author":"Wei","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0045","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.cr.7290370","article-title":"Roles of HIV-1 auxiliary proteins in viral pathogenesis and host-pathogen interactions","volume":"15","author":"Li","year":"2005","journal-title":"Cell Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0050","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41594-020-0463-z","article-title":"Structural basis of CD4 downregulation by HIV-1 Nef","volume":"27","author":"Kwon","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0055","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1084\/jem.176.4.1099","article-title":"Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis","volume":"176","author":"Banda","year":"1992","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2025.08.003_bb0060","doi-asserted-by":"crossref","DOI":"10.1172\/JCI171554","article-title":"The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy","volume":"133","author":"McMyn","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.08.003_bb0065","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbacli.2017.07.002","article-title":"Antioxidative activity of high-density lipoprotein (HDL): mechanistic insights into potential clinical benefit","volume":"8","author":"Brites","year":"2017","journal-title":"BBA Clin."},{"key":"10.1016\/j.molmed.2025.08.003_bb0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-981-19-1592-5_5","article-title":"HDL and oxidation","volume":"1377","author":"Zhang","year":"2022","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0075","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.atherosclerosis.2014.12.005","article-title":"Lipoprotein concentration, particle number, size and cholesterol efflux capacity are associated with mitochondrial oxidative stress and function in an HIV positive cohort","volume":"239","author":"Parikh","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmed.2025.08.003_bb0080","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1097\/QAD.0000000000001238","article-title":"Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection","volume":"30","author":"Kelesidis","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.molmed.2025.08.003_bb0085","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1161\/CIR.0000000000000695","article-title":"Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association","volume":"140","author":"Feinstein","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2025.08.003_bb0090","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/hiv.12843","article-title":"Rate of dyslipidemia higher among women living with HIV: a comparison of metabolic and cardiovascular health in a cohort to study aging in HIV","volume":"21","author":"Russell","year":"2020","journal-title":"HIV Med."},{"key":"10.1016\/j.molmed.2025.08.003_bb0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2015.08.036","article-title":"HIV infection induces structural and functional changes in high density lipoproteins","volume":"243","author":"Siegel","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmed.2025.08.003_bb0100","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV Infection and HAART on serum lipids in men","volume":"289","author":"Riddler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.molmed.2025.08.003_bb0105","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.08.003_bb0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.08.003_bb0115","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.1021\/bi100466q","article-title":"Mutation of the ATP cassette binding transporter A1 (ABCA1) C-terminus disrupts HIV-1 Nef binding but does not block the Nef enhancement of ABCA1 protein degradation","volume":"49","author":"Mujawar","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.molmed.2025.08.003_bb0120","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1161\/CIRCRESAHA.124.323891","article-title":"Inflammation in HIV and its impact on atherosclerotic cardiovascular disease","volume":"134","author":"Obare","year":"2024","journal-title":"Circ. Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0125","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1194\/jlr.M088153","article-title":"Cholesterol efflux responds to viral load and CD4 counts in HIV+ patients and is dampened in HIV exposed","volume":"59","author":"Tort","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0130","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/infdis\/jis723","article-title":"The expression of cholesterol metabolism genes in monocytes from HIV-infected subjects suggests intracellular cholesterol accumulation","volume":"207","author":"Feeney","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.molmed.2025.08.003_bb0135","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1371\/journal.pbio.0040365","article-title":"Human immunodeficiency virus impairs reverse cholesterol transport from macrophages","volume":"4","author":"Mujawar","year":"2006","journal-title":"PLoS Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0140","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1097\/QAD.0000000000000739","article-title":"Monocytes from HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration","volume":"29","author":"Maisa","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.molmed.2025.08.003_bb0145","doi-asserted-by":"crossref","first-page":"e1008869","DOI":"10.1371\/journal.ppat.1008869","article-title":"Macrophage maturation from blood monocytes is altered in people with HIV, and is linked to serum lipid profiles and activation indices: A model for studying atherogenic mechanisms","volume":"16","author":"Bowman","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molmed.2025.08.003_bb0150","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41392-022-01125-5","article-title":"Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics","volume":"7","author":"Duan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.molmed.2025.08.003_bb0155","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1194\/jlr.M054510","article-title":"Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: Impact of HAART","volume":"56","author":"El Khoury","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0160","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/acsptsci.9b00100","article-title":"The role of Toll-like receptors in atherothrombotic cardiovascular disease","volume":"3","author":"Zhou","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.molmed.2025.08.003_bb0165","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0022-2275(20)31566-2","article-title":"ABCA1. The gatekeeper for eliminating excess tissue cholesterol","volume":"42","author":"Oram","year":"2001","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cmet.2005.01.002","article-title":"ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation","volume":"1","author":"Kennedy","year":"2005","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2025.08.003_bb0175","doi-asserted-by":"crossref","first-page":"28870","DOI":"10.1074\/jbc.M114.583591","article-title":"HIV-1 protein NEF inhibits activity of ATP-binding cassette transporter A1 by targeting endoplasmic reticulum chaperone calnexin","volume":"289","author":"Jennelle","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.08.003_bb0180","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1194\/jlr.M023119","article-title":"HIV-1 Nef mobilizes lipid rafts in macrophages through a pathway that competes with ABCA1-dependent cholesterol efflux","volume":"53","author":"Cui","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0185","doi-asserted-by":"crossref","first-page":"13377","DOI":"10.1074\/jbc.RA120.014642","article-title":"Modification of lipid rafts by extracellular vesicles carrying HIV-1 protein Nef induces redistribution of amyloid precursor protein and Tau, causing neuronal dysfunction","volume":"295","author":"Ditiatkovski","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.08.003_bb0190","doi-asserted-by":"crossref","first-page":"e1007907","DOI":"10.1371\/journal.ppat.1007907","article-title":"Exosomes containing HIV protein Nef reorganize lipid rafts potentiating inflammatory response in bystander cells","volume":"15","author":"Mukhamedova","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molmed.2025.08.003_bb0195","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1742-4690-9-85","article-title":"Caveolin-1 reduces HIV-1 infectivity by restoration of HIV Nef mediated impairment of cholesterol efflux by apoA-I","volume":"9","author":"Lin","year":"2012","journal-title":"Retrovirology"},{"key":"10.1016\/j.molmed.2025.08.003_bb0200","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1016\/j.csbj.2021.06.050","article-title":"Direct interaction between ABCA1 and HIV-1 Nef: molecular modeling and virtual screening for inhibitors","volume":"19","author":"Adzhubei","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.molmed.2025.08.003_bb0205","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-981-15-6082-8_6","article-title":"ABC transporters, cholesterol efflux, and implications for cardiovascular diseases","volume":"1276","author":"Wang","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0210","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/01.ATV.0000144811.94581.52","article-title":"Cyclosporin A traps ABCA1 at the plasma membrane and inhibits ABCA1-mediated lipid efflux to apolipoprotein A-I","volume":"24","author":"Le Goff","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0215","doi-asserted-by":"crossref","first-page":"29277","DOI":"10.1074\/jbc.M505566200","article-title":"A PEST deletion mutant of ABCA1 shows impaired internalization and defective cholesterol efflux from late endosomes","volume":"280","author":"Chen","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.08.003_bb0220","doi-asserted-by":"crossref","first-page":"33053","DOI":"10.1074\/jbc.M005438200","article-title":"Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1","volume":"275","author":"Wang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.08.003_bb0225","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nchembio.268","article-title":"HIV-1 Nef membrane association depends on charge, curvature, composition and sequence","volume":"6","author":"Gerlach","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0230","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1172\/JCI200316808","article-title":"A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I","volume":"111","author":"Wang","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.08.003_bb0235","doi-asserted-by":"crossref","first-page":"100482","DOI":"10.1016\/j.jlr.2023.100482","article-title":"Functional characterization of missense variants affecting the extracellular domains of ABCA1 using a fluorescence-based assay","volume":"65","author":"Teigen","year":"2024","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1106591","article-title":"Novel role of HIV-1 Nef in regulating the ubiquitination of cellular proteins","volume":"13","author":"Ghaly","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0245","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1146\/annurev.biochem.73.011303.073752","article-title":"Roles of N-linked glycans in the endoplasmic reticulum","volume":"73","author":"Helenius","year":"2004","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.molmed.2025.08.003_bb0250","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbrc.2006.06.032","article-title":"Calreticulin facilitates the cell surface expression of ABCG5\/G8","volume":"347","author":"Okiyoneda","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2025.08.003_bb0255","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1161\/ATVBAHA.116.307997","article-title":"Interaction between HIV-1 nef and calnexin: from modeling to small molecule inhibitors reversing HIV-induced lipid accumulation","volume":"36","author":"Hunegnaw","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0260","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/cvr\/cvq075","article-title":"Caveolae, caveolins, and cavins: complex control of cellular signalling and inflammation","volume":"86","author":"Chidlow","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0265","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12977-015-0188-y","article-title":"HIV inhibits endothelial reverse cholesterol transport through impacting subcellular caveolin-1 trafficking","volume":"12","author":"Lin","year":"2015","journal-title":"Retrovirology"},{"key":"10.1016\/j.molmed.2025.08.003_bb0270","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/aid.2014.0239","article-title":"Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens","volume":"31","author":"Munger","year":"2015","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.molmed.2025.08.003_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215620","article-title":"HIV disease, metabolic dysfunction and atherosclerosis: a three year prospective study","volume":"14","author":"Low","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2025.08.003_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2022.02.012","article-title":"The role of HDL- and non-HDL-related parameters in cell-cholesterol efflux capacity","volume":"345","author":"Asztalos","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmed.2025.08.003_bb0285","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCRESAHA.119.312617","article-title":"HDL and reverse cholesterol transport","volume":"124","author":"Ouimet","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0290","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.atherosclerosis.2007.10.018","article-title":"HIV infection and high density lipoprotein metabolism","volume":"199","author":"Rose","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmed.2025.08.003_bb0295","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2013.04.010","article-title":"The effect of HIV infection on atherosclerosis and lipoprotein metabolism: a one year prospective study","volume":"229","author":"Rose","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmed.2025.08.003_bb0300","article-title":"Greater IL-6, D-dimer, and ICAM-1 Levels are associated with lower small HDL particle concentration in the multicenter AIDS cohort study. Open Forum","volume":"6","author":"Sarkar","year":"2019","journal-title":"Infect. Dis."},{"key":"10.1016\/j.molmed.2025.08.003_bb0305","article-title":"High-density lipoprotein-mediated cholesterol efflux capacity is improved by treatment with antiretroviral therapy in acute human immunodeficiency virus infection. Open Forum","volume":"1","author":"Lo","year":"2014","journal-title":"Infect. Dis."},{"key":"10.1016\/j.molmed.2025.08.003_bb0310","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1476-511X-10-35","article-title":"HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL","volume":"10","author":"Kelesidis","year":"2011","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.molmed.2025.08.003_bb0315","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jinf.2017.11.008","article-title":"Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients","volume":"76","author":"Satta","year":"2018","journal-title":"J. Infect."},{"key":"10.1016\/j.molmed.2025.08.003_bb0320","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3851\/IMP3091","article-title":"Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity","volume":"22","author":"Funderburg","year":"2017","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.molmed.2025.08.003_bb0325","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.atherosclerosis.2008.09.016","article-title":"Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice","volume":"204","author":"Tohyama","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmed.2025.08.003_bb0330","doi-asserted-by":"crossref","first-page":"304","DOI":"10.2353\/ajpath.2007.060965","article-title":"Human immunodeficiency virus protease inhibitor ritonavir inhibits cholesterol efflux from human macrophage-derived foam cells","volume":"171","author":"Wang","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0335","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/labinvest.2009.85","article-title":"Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells","volume":"89","author":"Wang","year":"2009","journal-title":"Lab. Investig."},{"key":"10.1016\/j.molmed.2025.08.003_bb0340","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.atherosclerosis.2009.02.042","article-title":"Antiretroviral compounds and cholesterol efflux from macrophages","volume":"206","author":"Mukhamedova","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmed.2025.08.003_bb0345","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1210\/jc.2017-01334","article-title":"HDL cholesterol efflux capacity in newly diagnosed HIV and effects of antiretroviral therapy","volume":"102","author":"Toribio","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2025.08.003_bb0350","doi-asserted-by":"crossref","first-page":"100602","DOI":"10.1016\/j.ijregi.2025.100602","article-title":"Changes in the lipid profile in people with HIV after one year of antiretroviral therapy \u2013 the significance of immune parameters","volume":"14","author":"Lembas","year":"2025","journal-title":"IJID Reg."},{"key":"10.1016\/j.molmed.2025.08.003_bb0355","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/infdis\/jiac301","article-title":"Increased macrophage-specific arterial infiltration relates to noncalcified plaque and systemic immune activation in people with human immunodeficiency virus","volume":"226","author":"Toribio","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.molmed.2025.08.003_bb0360","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4172\/2155-6113.1000317","article-title":"Cardiovascular disease-risk markers in HIV patients","volume":"5","author":"Asztalos","year":"2014","journal-title":"J. AIDS Clin. Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0365","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1097\/QAI.0b013e318186519c","article-title":"HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients","volume":"49","author":"Kotler","year":"2008","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.molmed.2025.08.003_bb0370","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1161\/ATVBAHA.109.192088","article-title":"Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production","volume":"29","author":"Franssen","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0375","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-511X-11-69","article-title":"Retinoic acid and liver X receptor agonist synergistically inhibit HIV infection in CD4+ T cells by up-regulating ABCA1-mediated cholesterol efflux","volume":"11","author":"Jiang","year":"2012","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.molmed.2025.08.003_bb0380","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/mol.110.065029","article-title":"Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1","volume":"78","author":"Morrow","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0385","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bbrc.2012.01.137","article-title":"Liver X receptor agonist inhibits HIV-1 replication and prevents HIV-induced reduction of plasma HDL in humanized mouse model of HIV infection","volume":"419","author":"Dubrovsky","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2025.08.003_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000981","article-title":"PPAR\u03b3 and LXR signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infection","volume":"6","author":"Hanley","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molmed.2025.08.003_bb0395","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01031-13","article-title":"Alterations in cholesterol metabolism restrict HIV-1 trans infection in nonprogressors","volume":"5","author":"Rappocciolo","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.molmed.2025.08.003_bb0400","article-title":"Inhibition of HIV replication by apolipoprotein A-I binding protein targeting the lipid rafts","volume":"11","author":"Dubrovsky","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.molmed.2025.08.003_bb0405","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1016\/j.jacc.2017.05.012","article-title":"HIV-1\u2013associated atherosclerosis","volume":"69","author":"Kearns","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0410","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.08.003_bb0415","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/COH.0000000000000953","article-title":"Understanding residual risk of cardiovascular disease in people with HIV","volume":"20","author":"Obare","year":"2025","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.molmed.2025.08.003_bb0420","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/jamacardio.2023.5661","article-title":"Effects of pitavastatin on coronary artery disease and inflammatory biomarkers in HIV: mechanistic substudy of the REPRIEVE randomized clinical trial","volume":"9","author":"Lu","year":"2024","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0425","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0014-5793(02)03578-0","article-title":"T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice","volume":"536","author":"Terasaka","year":"2003","journal-title":"FEBS Lett."},{"key":"10.1016\/j.molmed.2025.08.003_bb0430","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1161\/ATVBAHA.109.194548","article-title":"Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent","volume":"29","author":"Larrede","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0435","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-2261-14-80","article-title":"Cholesterol efflux is LXR\u03b1 isoform-dependent in human macrophages","volume":"14","author":"Ma","year":"2014","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.molmed.2025.08.003_bb0440","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00011-011-0433-3","article-title":"Lipopolysaccharide represses the expression of ATP-binding cassette transporter G1 and scavenger receptor class B, type I in murine macrophages","volume":"61","author":"Park","year":"2012","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0445","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bbrc.2015.06.150","article-title":"Regulation of retinoid mediated cholesterol efflux involves liver X receptor activation in mouse macrophages","volume":"464","author":"Manna","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2025.08.003_bb0450","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.bbrc.2016.11.123","article-title":"Activation of PPAR\u03b3 does not contribute to macrophage ABCA1 expression and ABCA1-mediated cholesterol efflux to apoAI","volume":"482","author":"Jiang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2025.08.003_bb0455","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1124\/jpet.115.224485","article-title":"Stimulation of liver X receptor has potent anti-HIV effects in a humanized mouse model of HIV infection","volume":"354","author":"Ramezani","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2025.08.003_bb0460","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.bbalip.2011.08.009","article-title":"Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits. Biochim. Biophys. Acta BBA - Mol","volume":"1811","author":"Honzumi","year":"2011","journal-title":"Cell Biol. Lipids"},{"key":"10.1016\/j.molmed.2025.08.003_bb0465","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1194\/jlr.M800374-JLR200","article-title":"LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms","volume":"50","author":"Verschuren","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0470","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1194\/jlr.M400257-JLR200","article-title":"Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor","volume":"45","author":"Quinet","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0475","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1194\/jlr.M800376-JLR200","article-title":"Synthetic LXR agonist attenuates plaque formation in apoE-\/- mice without inducing liver steatosis and hypertriglyceridemia","volume":"50","author":"Kratzer","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0480","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.3390\/nu12103088","article-title":"Endoplasmic reticulum stress affects cholesterol homeostasis by inhibiting LXR\u03b1 expression in hepatocytes and macrophages","volume":"12","author":"Wang","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.molmed.2025.08.003_bb0485","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1479-5876-6-59","article-title":"Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells","volume":"6","author":"DiBlasio-Smith","year":"2008","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.molmed.2025.08.003_bb0490","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1194\/jlr.M900037-JLR200","article-title":"LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse","volume":"50","author":"Quinet","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0495","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/0091270009335768","article-title":"Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants","volume":"49","author":"Katz","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0500","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/meta.2003.50100","article-title":"Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages","volume":"52","author":"Cabrero","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.molmed.2025.08.003_bb0505","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1161\/01.ATV.0000163844.07815.c4","article-title":"Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I\u2013mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor\u2013dependent manner","volume":"25","author":"Arakawa","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0510","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.2337\/diabetes.51.12.3486","article-title":"Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients","volume":"51","author":"Forcheron","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.molmed.2025.08.003_bb0515","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbalip.2010.11.006","article-title":"Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo. Biochim. Biophys. Acta BBA - Mol","volume":"1811","author":"Rotllan","year":"2011","journal-title":"Cell Biol. Lipids"},{"key":"10.1016\/j.molmed.2025.08.003_bb0520","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jacl.2013.06.007","article-title":"Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients","volume":"7","author":"Franceschini","year":"2013","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00126334-200209010-00001","article-title":"Stimulation of peroxisome proliferator-activated receptors \u03b1 and \u03b3 blocks HIV-1 replication and TNF\u03b1 production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects","volume":"31","author":"Skolnik","year":"2002","journal-title":"Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.molmed.2025.08.003_bb0530","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.carpath.2008.03.001","article-title":"Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbits","volume":"18","author":"Jeanpierre","year":"2009","journal-title":"Cardiovasc. Pathol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0535","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1161\/01.ATV.0000238348.05028.14","article-title":"Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol","volume":"26","author":"Kooistra","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0540","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmed.2025.08.003_bb0545","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.atherosclerosis.2011.07.113","article-title":"Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1\/ABCG1 expressions via PPAR\u03b3\/LXR\u03b1 pathway: findings from in vitro and ex vivo studies","volume":"219","author":"Ozasa","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmed.2025.08.003_bb0550","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1128\/JVI.00789-11","article-title":"Nuclear receptor signaling inhibits HIV-1 replication in macrophages through multiple trans -repression mechanisms","volume":"85","author":"Hanley","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0555","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/CIRCRESAHA.110.219089","article-title":"Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell\u2013specific interaction with PPAR\u03b3","volume":"107","author":"Subramanian","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0560","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1210\/clinem\/dgz252","article-title":"Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis","volume":"105","author":"Zhou","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2025.08.003_bb0565","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jacc.2010.06.055","article-title":"Lowering the triglyceride\/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients","volume":"57","author":"Nicholls","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0570","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.bcp.2008.08.005","article-title":"The RXR agonists PA024 and HX630 have different abilities to activate LXR\/RXR and to induce ABCA1 expression in macrophage cell lines","volume":"76","author":"Nishimaki-Mogami","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181055","article-title":"Suppressive effects of RXR agonist PA024 on adrenal CYP11B2 expression, aldosterone secretion and blood pressure","volume":"12","author":"Suzuki","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2025.08.003_bb0580","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.yjmcc.2006.07.022","article-title":"A new RXR agonist, HX630, suppresses intimal hyperplasia in a mouse blood flow cessation model","volume":"41","author":"Haraguchi","year":"2006","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0585","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bbalip.2012.02.004","article-title":"Retinoic acid receptor agonists regulate expression of ATP-binding cassette transporter G1 in macrophages","volume":"1821","author":"Ayaori","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.molmed.2025.08.003_bb0590","doi-asserted-by":"crossref","first-page":"7756","DOI":"10.1128\/MCB.23.21.7756-7766.2003","article-title":"Retinoic acid receptor-mediated induction of ABCA1 in macrophages","volume":"23","author":"Costet","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0595","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1620\/tjem.220.223","article-title":"D-4F, an apolipoprotein A-I mimetic peptide, promotes cholesterol efflux from macrophages via ATP-binding cassette transporter A1","volume":"220","author":"Xie","year":"2010","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.molmed.2025.08.003_bb0600","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/01.CIR.0000134275.90823.87","article-title":"Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice","volume":"109","author":"Navab","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2025.08.003_bb0605","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/hc0302.103711","article-title":"Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol","volume":"105","author":"Navab","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2025.08.003_bb0610","doi-asserted-by":"crossref","first-page":"154888","DOI":"10.1016\/j.metabol.2021.154888","article-title":"ApoA-I mimetics favorably impact cyclooxygenase 2 and bioactive lipids that may contribute to cardiometabolic syndrome in chronic treated HIV","volume":"124","author":"Daskou","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.molmed.2025.08.003_bb0615","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1194\/jlr.M073270","article-title":"AMPK activation enhances the anti-atherogenic effects of high density lipoproteins in apoE\u2212\/\u2212 mice","volume":"58","author":"Ma","year":"2017","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biocel.2016.06.014","article-title":"AMPK activates LXR\u03b1 and ABCA1 expression in human macrophages","volume":"78","author":"Kemmerer","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2023.113784","article-title":"AMPK activators suppress cholesterol accumulation in macrophages via suppression of the mTOR pathway","volume":"432","author":"Owaki","year":"2023","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0630","doi-asserted-by":"crossref","first-page":"33499","DOI":"10.1074\/jbc.M110.159772","article-title":"Adenosine monophosphate-activated protein kinase induces cholesterol efflux from macrophage-derived foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice","volume":"285","author":"Li","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.08.003_bb0635","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.virusres.2009.08.005","article-title":"SIRT1 regulates Tat-induced HIV-1 transactivation through activating AMP-activated protein kinase","volume":"146","author":"Zhang","year":"2009","journal-title":"Virus Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0640","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1194\/jlr.M058875","article-title":"Salicylate improves macrophage cholesterol homeostasis via activation of Ampk","volume":"56","author":"Fullerton","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0645","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s13577-023-00950-2","article-title":"M1 linear ubiquitination of LKB1 inhibits vascular endothelial cell injury in atherosclerosis through activation of AMPK","volume":"36","author":"Huangfu","year":"2023","journal-title":"Hum. Cell"},{"key":"10.1016\/j.molmed.2025.08.003_bb0650","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/abbs\/36.3.218","article-title":"Effect of apolipoprotein A-I on ATP binding cassette transporter A1 degradation and cholesterol efflux in THP-1 macrophage-derived foam cells","volume":"36","author":"Tang","year":"2004","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.molmed.2025.08.003_bb0655","doi-asserted-by":"crossref","first-page":"22426","DOI":"10.1074\/jbc.M202996200","article-title":"Helical apolipoproteins stabilize ATP-binding cassette transporter A1 by protecting it from thiol protease-mediated degradation","volume":"277","author":"Arakawa","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.08.003_bb0660","doi-asserted-by":"crossref","first-page":"10463","DOI":"10.1021\/bi00033a019","article-title":"Effect and cellular site of action of cysteine protease inhibitors on the cholesterol esterification pathway in macrophages and Chinese hamster ovary cells","volume":"34","author":"Schissel","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.molmed.2025.08.003_bb0665","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1139\/cjpp-2016-0652","article-title":"Calpain inhibitor I attenuates atherosclerosis and inflammation in atherosclerotic rats through eNOS\/NO\/NF-\u03baB pathway","volume":"96","author":"Yu","year":"2018","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0670","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1194\/jlr.M054742","article-title":"Inhibition of ABCA1 protein degradation promotes HDL cholesterol efflux capacity and RCT and reduces atherosclerosis in mice","volume":"56","author":"Huang","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114732","article-title":"IMM-H007, a novel small molecule inhibitor for atherosclerosis, represses endothelium inflammation by regulating the activity of NF-\u03baB and JNK\/AP1 signaling","volume":"381","author":"Yu","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0680","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/ATVBAHA.115.306376","article-title":"Probucol-oxidized products, spiroquinone and diphenoquinone, promote reverse cholesterol transport in mice","volume":"36","author":"Yakushiji","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0685","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1194\/jlr.M900122-JLR200","article-title":"Pharmacological inhibition of ABCA1 degradation increases HDL biogenesis and exhibits antiatherogenesis","volume":"50","author":"Arakawa","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0690","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1189\/jlb.0709513","article-title":"A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux","volume":"87","author":"Bingham","year":"2010","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0695","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.bbalip.2012.11.005","article-title":"Adenosine A(2A) receptor activation supports an atheroprotective cholesterol balance in human macrophages and endothelial cells","volume":"1831","author":"Voloshyna","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.molmed.2025.08.003_bb0700","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2010.07.024","article-title":"Cilostazol enhances macrophage reverse cholesterol transport in vitro and in vivo","volume":"213","author":"Nakaya","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmed.2025.08.003_bb0705","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/ATVBAHA.108.164368","article-title":"Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells","volume":"28","author":"Ota","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0710","doi-asserted-by":"crossref","first-page":"503","DOI":"10.5551\/jat.3392","article-title":"Anti-inflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo","volume":"17","author":"Aoki","year":"2010","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.molmed.2025.08.003_bb0715","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1124\/jpet.104.079780","article-title":"Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol","volume":"313","author":"Lee","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2025.08.003_bb0720","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2018.01.019","article-title":"Phosphodiesterase-3 inhibitor cilostazol reverses endothelial dysfunction with ageing in rat mesenteric resistance arteries","volume":"822","author":"Moreira","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0725","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/fcp.12195","article-title":"Cilostazol exerts antiplatelet and anti-inflammatory effects through AMPK activation and NF-kB inhibition on hypercholesterolemic rats","volume":"30","author":"da Motta","year":"2016","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0730","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00380-010-0093-1","article-title":"Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up","volume":"26","author":"Ahn","year":"2011","journal-title":"Heart Vessel."},{"key":"10.1016\/j.molmed.2025.08.003_bb0735","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s102380300004","article-title":"Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease","volume":"2","author":"Nakamura","year":"2003","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.molmed.2025.08.003_bb0740","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.phrs.2007.04.007","article-title":"Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients","volume":"56","author":"Agrawal","year":"2007","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.molmed.2025.08.003_bb0745","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1093\/eurheartj\/ehn287","article-title":"A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study","volume":"29","author":"Angiolillo","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.molmed.2025.08.003_bb0750","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1006\/bbrc.2001.6259","article-title":"Cyclic AMP-specific phosphodiesterase 4 inhibitors promote ABCA1 expression and cholesterol efflux","volume":"290","author":"Lin","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2025.08.003_bb0755","doi-asserted-by":"crossref","DOI":"10.1177\/1179555717694535","article-title":"cAMP signaling enhances HIV-1 long terminal repeat (LTR)-directed transcription and viral replication in bone marrow progenitor cells","volume":"10","author":"Banerjee","year":"2017","journal-title":"Clin. Med. Insights Pathol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0760","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/aid.1992.8.1255","article-title":"Human immunodeficiency virus replication: modulation by cellular levels of cAMP","volume":"8","author":"Nokta","year":"1992","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.molmed.2025.08.003_bb0765","first-page":"1755","article-title":"(2000) Infection of CD4+ memory T cells by HIV-1 requires expression of phosphodiesterase 4","volume":"165","author":"Sun","year":"1950","journal-title":"J. Immunol. Baltim. Md"},{"key":"10.1016\/j.molmed.2025.08.003_bb0770","doi-asserted-by":"crossref","first-page":"9638","DOI":"10.1111\/jcmm.15476","article-title":"The cyclic adenosine monophosphate elevating medicine, forskolin, reduces neointimal formation and atherogenesis in mice","volume":"24","author":"Hao","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.molmed.2025.08.003_bb0775","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2014.02.008","article-title":"MicroRNA-27a\/b regulates cellular cholesterol efflux, influx and esterification\/hydrolysis in THP-1 macrophages","volume":"234","author":"Zhang","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmed.2025.08.003_bb0780","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1128\/JVI.05065-11","article-title":"Regulation of cyclin T1 and HIV-1 replication by microRNAs in resting CD4+ T lymphocytes","volume":"86","author":"Chiang","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0785","article-title":"MicroRNA-27 prevents atherosclerosis by suppressing lipoprotein lipase-induced lipid accumulation and inflammatory response in apolipoprotein E knockout mice","volume":"11","author":"Xie","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2025.08.003_bb0790","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109722","article-title":"Effects of miR-33a-5P on ABCA1\/G1-mediated cholesterol efflux under inflammatory stress in THP-1 macrophages","volume":"9","author":"Mao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2025.08.003_bb0795","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.003376","article-title":"MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE \u2212\/\u2212 Mice","volume":"1","author":"Horie","year":"2012","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.molmed.2025.08.003_bb0800","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/ATVBAHA.113.302701","article-title":"MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice","volume":"34","author":"Du","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0805","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002937","article-title":"A role for microRNA-155 modulation in the anti-HIV-1 effects of Toll-like receptor 3 stimulation in macrophages","volume":"8","author":"Swaminathan","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molmed.2025.08.003_bb0810","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/hiv.12470","article-title":"MicroRNA-155 is a biomarker of T-cell activation and immune dysfunction in HIV-1-infected patients","volume":"18","author":"Jin","year":"2017","journal-title":"HIV Med."},{"key":"10.1016\/j.molmed.2025.08.003_bb0815","article-title":"miR-155 acts as an anti-inflammatory factor in atherosclerosis-associated foam cell formation by repressing calcium-regulated heat stable protein 1","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2025.08.003_bb0820","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/ATVBAHA.114.304723","article-title":"Regulation of Csf1r and Bcl6 in macrophages mediates the stage-specific effects of microRNA-155 on atherosclerosis","volume":"35","author":"Wei","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0825","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/14728222.2022.2117610","article-title":"Liver X receptor: a potential target in the treatment of atherosclerosis","volume":"26","author":"Savla","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.molmed.2025.08.003_bb0830","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/metabo11090640","article-title":"Combined LXR and RXR agonist therapy increases ABCA1 protein expression and enhances ApoAI-mediated cholesterol efflux in cultured endothelial cells","volume":"11","author":"Huang","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.molmed.2025.08.003_bb0835","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1021\/acs.jmedchem.1c00235","article-title":"Oxaprozin analogues as selective RXR agonists with superior properties and pharmacokinetics","volume":"64","author":"Schierle","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2025.08.003_bb0840","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1074\/jbc.M605023200","article-title":"The liver X receptor (LXR) and hepatic lipogenesis","volume":"282","author":"Cha","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.08.003_bb0845","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/cmdc.201600305","article-title":"Development of tetrachlorophthalimides as liver X receptor \u03b2 (LXR\u03b2)-selective agonists","volume":"11","author":"Nomura","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.molmed.2025.08.003_bb0850","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1147699","article-title":"Targeting macrophages in atherosclerosis using nanocarriers loaded with liver X receptor agonists: a narrow review","volume":"10","author":"Yang","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.molmed.2025.08.003_bb0855","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jconrel.2020.11.016","article-title":"Synthetic high-density lipoproteins delivering liver X receptor agonist prevent atherogenesis by enhancing reverse cholesterol transport","volume":"329","author":"Yuan","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2025.08.003_bb0860","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12951-024-02529-x","article-title":"High-density lipoprotein mimetic nano-therapeutics targeting monocytes and macrophages for improved cardiovascular care: a comprehensive review","volume":"22","author":"Zhen","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0865","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1021\/acs.jmedchem.8b01848","article-title":"Tuning nuclear receptor selectivity of Wy14,643 towards selective retinoid X receptor modulation","volume":"62","author":"Pollinger","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2025.08.003_bb0870","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2019.08.043","article-title":"Anti-atherosclerotic effects of an improved apolipoprotein A-I mimetic peptide","volume":"297","author":"Suematsu","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0875","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.yjmcc.2017.01.017","article-title":"The apolipoprotein A-I mimetic peptide, D-4F, alleviates ox-LDL-induced oxidative stress and promotes endothelial repair through the eNOS\/HO-1 pathway","volume":"105","author":"Liu","year":"2017","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.molmed.2025.08.003_bb0880","doi-asserted-by":"crossref","first-page":"111900","DOI":"10.1016\/j.biopha.2021.111900","article-title":"High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis","volume":"141","author":"Kudinov","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.molmed.2025.08.003_bb0885","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/biomedicines8100373","article-title":"Cholesterol efflux efficiency of reconstituted HDL is affected by nanoparticle lipid composition","volume":"8","author":"Jebari-Benslaiman","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.molmed.2025.08.003_bb0890","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ebiom.2017.12.021","article-title":"Synthetic high-density lipoprotein-mediated targeted delivery of liver X Receptors agonist promotes atherosclerosis regression","volume":"28","author":"Guo","year":"2018","journal-title":"EBioMedicine"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425001911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425001911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:29:09Z","timestamp":1783027749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491425001911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":178,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1471491425001911"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2025.08.003","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cholesterol efflux in HIV-associated atherosclerosis: mechanisms and targets","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2025.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}